Proteome Sciences Increases Loan to $12M; Will Ensure Solvency Until ProtoShop Revenue Appears | GenomeWeb
NEW YORK (GenomeWeb News) — Proteome Sciences' CEO Christopher Pearce has increased an existing loan facility to the company from £4 million ($8 million) to £6 million, the company said today.
 
Proteome said the additional cash will keep the company solvent until it starts recording revenue from its ProteoShop biomarker portfolio.
 
The expanded facility will also enable the firm to out-license its TMT products, which it expects to happen sometime during the next five months.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.